Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 7, 2017; 23(13): 2396-2403
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2396
Table 4 Multivariate analysis for complete virological response after 12 mo of tenofovir disoproxil fumarate therapy
Regression coefficient | Standard error | OR (95%CI) | P value | |
Age (per year) | -0.018 | 0.022 | 0.982 (0.941-1.025) | 0.412 |
Sex | 0.427 | 0.543 | 1.533 (0.529-4.439) | 0.431 |
ALT level (per 1 IU/L) | 0.001 | 0.001 | 1.001 (0.999-1.003) | 0.342 |
HBeAg | 1.726 | 0.524 | 5.617 (2.011-15.689) | 0.001 |
Positivity | ||||
Negativity | ||||
Baseline HBV DNA (per 1 log10 copies/mL) | 0.117 | 0.184 | 1.124 (0.784-1.611) | 0.525 |
Diagnosis | -1.080 | 0.456 | 0.340 (0.139-0.829) | 0.018 |
Compensated | ||||
Decompensated |
- Citation: Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017; 23(13): 2396-2403
- URL: https://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i13.2396